Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 2 1

Status

Unknown 19Recruiting 9Not yet recruiting 5Active not recruiting 4Completed 3

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 4Stomach Neoplasms 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Diseases 1Neoplasms by Site 1Neoplasms 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Biliary Tract Carcinoma 1

Interventions

durvalumab 18Bevacizumab 18atezolizumab 13lenvatinib 10Magnetic Resonance Spectroscopy 9tremelimumab 8Nivolumab 8pembrolizumab 7Sorafenib 6Specimen Handling 5camrelizumab 4cabozantinib 4Immunoglobulin G 4Disulfides 4apatinib 3X-Rays 3Radiotherapy 3Radiofrequency Ablation 3Radiation 3Hepatectomy 3E-7386 3Doxorubicin 3Cyclophosphamide 3tislelizumab 2sintilimab 2relatlimab 2dostarlimab 2budigalimab 2Standard of Care 2Simvastatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Hepatocellular × camrelizumab × Clear all
NCT05198609 2026-01-21

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Sun Yat-sen University

Phase 3 Active not recruiting
214 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Active not recruiting
687 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04521153 2025-05-11

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Shanghai Zhongshan Hospital

Phase 2/3 Active not recruiting
294 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04483284 2024-08-01

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

Shanghai Zhongshan Hospital

Phase 2 Active not recruiting
28 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡